Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : SARS-CoV-2 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Merck & Co
Deal Size : Undisclosed
Deal Type : Acquisition
Merck Completes Acquisition of Themis
Details :
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
June 19, 2020
Lead Product(s) : SARS-CoV-2 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Merck & Co
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : SARS-CoV-2 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Merck & Co
Deal Size : Undisclosed
Deal Type : Acquisition
Details :
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
May 26, 2020
Lead Product(s) : SARS-CoV-2 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Merck & Co
Deal Size : Undisclosed
Deal Type : Acquisition